サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1696282

急性心筋梗塞（AMI）の世界市場（2025年～2033年）

Global Acute Myocardial Infarction Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
急性心筋梗塞（AMI）の世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の急性心筋梗塞（AMI）の市場規模は、2024年に17億9,079万米ドルに達し、2033年までに30億6,581万米ドルに達すると予測され、2025年～2033年の予測期間にCAGRで6.7%の成長が見込まれます。

世界の急性心筋梗塞（AMI）市場には、世界規模での心臓発作の診断、治療、管理を目的とした幅広い医療ソリューションが含まれます。この市場には、抗血小板薬、血栓溶解薬、抗凝固薬などの医薬品による介入が含まれ、血栓のさらなる形成を防ぎ、心臓への血流を回復させる上で重要な役割を果たします。

さらに、ステント、カテーテル、除細動器などの医療機器は、緊急および長期的な心臓治療に不可欠です。市場はまた、早期発見とリスク評価を可能にし、患者の生存率を向上させ、合併症を減少させる先進の診断ツールもカバーしています。医薬品や医療機器だけでなく、急性心筋梗塞（AMI）市場には経皮的冠動脈形成術（PCI）や冠動脈バイパス術（CABG）といった外科的介入も含まれ、これらは心臓への血液供給を回復させる上で極めて重要です。

市場力学

促進要因と抑制要因

高齢化と心血管疾患の有病率の増加

高齢化と心血管疾患の有病率の増加が、予測期間の世界の急性心筋梗塞（AMI）市場の成長を促進します。高齢化に伴い、高血圧、冠動脈疾患、心不全などの心臓関連疾患を発症しやすくなり、急性心筋梗塞（AMI）のリスクが大幅に高まります。

2023年9月のNational Library of Medicineのデータによると、急性心筋梗塞（AMI）は依然として先進国の主要な死因であり、世界のAMI市場における重大な懸念です。世界中で約300万人がこの疾患に罹患しており、米国だけでも年間100万人超が死亡しています。

致死的なAMI患者の約70%は、動脈硬化性プラークの蓄積による動脈閉塞に関連しており、アテローム性動脈硬化が心臓発作の根本的な原因となっています。AMIにおける動脈硬化の重要な役割を考慮すると、市場では、動脈硬化性疾患に対処しAMI関連死亡率を低下させるための予防戦略、危険因子管理、革新的な治療ソリューションにますます焦点が当てられています。これらすべての要因が、世界の急性心筋梗塞（AMI）市場に需要をもたらしています。

世界の急性心筋梗塞（AMI）市場の大幅な成長は、この疾患の高い有病率、治療オプションの進歩、予防医療への取り組み、技術革新などの複合的な要因によってもたらされています。早期発見、介入、AMI治療後のケア強化に向けた研究が進むにつれ、市場はさらに拡大し、業界参入企業に新たな機会をもたらしています。

AMI治療と心臓手術の高いコスト

AMI治療と心臓手術の高いコストが、世界の急性心筋梗塞（AMI）市場における大きな抑制要因となっています。AMIの治療には、医薬品による治療、医療機器、経皮的冠動脈形成術（PCI）や冠動脈バイパス術（CABG）などの外科的介入が組み合わされることが多いです。このような高いコストが、特に低所得層や発展途上地域などの医療資源に制約の多い地域では、患者の最適な治療へのアクセスを制限する可能性があります。さらに、AMI発症後に必要とされる長期的なケアやリハビリテーションは、患者や医療制度の経済的負担を増大させます。

American Heart Association, Inc.の2024年2月の調査データによると、治療の経済的負担は必要とされる介入によって大きく異なります。経皮的冠動脈形成術（PCI）や冠動脈バイパス術（CABG）を行わずにAMIを管理するコストはもっとも低く、平均2万1,898ドルです。

しかし、PCIを必要とするAMI患者では約3万1,522ドル、CABGを必要とする患者では7万1,788ドルと、これらの治療を行わない場合の3倍を超える費用がかかります。このような高額な治療費は世界のAMI市場において大きな抑制要因となっており、医療へのアクセス、償還政策、心血管治療全体の費用対効果に影響を及ぼしています。したがって、上記の要因が世界の急性心筋梗塞（AMI）市場の潜在的な成長を制限している可能性があります。

当レポートでは、世界の急性心筋梗塞（AMI）市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：治療タイプ別
  • 抜粋：投与経路別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 高齢化と心血管疾患の有病率の増加
      • 低侵襲手術の需要の増加
    • 抑制要因
      • AMI治療と心臓手術の高いコスト
      • 急性心筋梗塞（AMI）の新しい治療薬とデバイスに対する厳格な規制承認
    • 機会
      • 薬物療法の利用の拡大
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 急性心筋梗塞（AMI）市場：治療タイプ別

  • コルヒチン
  • テネクテプラーゼ
  • エンパグリフロジン
  • 抗血小板薬
    • アスピリン
    • クロピドグレル
    • プラスグレル
    • チカグレロル
  • 抗凝固剤
    • 未分画ヘパリン（UFH）
    • エノキサパリン
    • ダルテパリン
    • ビバリルジン
    • チンザパリン
  • 糖タンパク質IIb/IIIa阻害薬
  • 抗狭心症治療
  • β遮断薬
  • ACE阻害薬
  • スタチン
  • デバイス
  • その他

第6章 急性心筋梗塞（AMI）市場：投与経路別

  • 経口
  • 静脈（IV）
  • その他

第7章 急性心筋梗塞（AMI）市場：地域別、市場の分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第8章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリクス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第9章 企業プロファイル

  • AGEPHA Pharma FZ-LLC.
  • Genentech, Inc.
  • Sanofi
  • Boehringer Ingelheim International GmbH. (Eli Lilly and Company)
  • Bayer AG
  • Daiichi Sankyo Company, Limited
  • AstraZeneca.
  • Pfizer Inc.
  • Fresenius Kabi
  • Viatris Inc. (Idorsia)

第10章 前提条件と調査手法

第11章 付録

目次
Product Code: PH9376

The global acute myocardial infarction market reached US$ 1,790.79 million in 2024 and is expected to reach US$ 3,065.81 million by 2033, growing at a CAGR of 6.7 % during the forecast period of 2025-2033.

The global acute myocardial infarction market encompasses a wide range of medical solutions aimed at the diagnosis, treatment and management of heart attacks on a global scale. This market includes pharmaceutical interventions such as antiplatelet agents, thrombolytics and anticoagulants, which play a crucial role in preventing further clot formation and restoring blood flow to the heart.

Additionally, medical devices such as stents, catheters and defibrillators are essential in emergency and long-term cardiac care. The market also covers advanced diagnostic tools that enable early detection and risk assessment, improving patient survival rates and reducing complications. Beyond pharmaceuticals and medical devices, the acute myocardial infarction market also includes surgical interventions like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), which are critical in restoring blood supply to the heart.

Market Dynamics: Drivers & Restraints

Aging Population and Increasing Prevalence of Cardiovascular Conditions

The aging population and increasing prevalence of cardiovascular conditions are expected to drive the growth of the global acute myocardial infarction market over the forecast period. As people age, they are more prone to developing heart-related conditions such as hypertension, coronary artery disease, and heart failure, which significantly increase the risk of acute myocardial infarction.

As per National Library of Medicine data in September 2023, acute myocardial infarction (AMI) remains a major contributor to mortality in the developed world and a significant concern in the global AMI market. The disease affects approximately 3 million people worldwide, with over 1 million deaths occurring annually in the United States alone.

Around 70% of fatal AMI cases are linked to arterial occlusion caused by atherosclerotic plaque buildup, making atherosclerosis the primary underlying cause of heart attacks. Given its critical role in AMI, the market increasingly focuses on preventive strategies, risk factor management, and innovative treatment solutions to address atherosclerotic disease and reduce AMI-related mortality. All these factors demand the global acute myocardial infarction market.

The significant growth in the global AMI market is being driven by a combination of factors, including the high prevalence of the disease, advancements in treatment options, preventive healthcare efforts, and technological innovations. As research continues to enhance early detection, intervention, and post-AMI care, the market is poised for further expansion, creating new opportunities for industry players.

High Cost of AMI Treatment & Cardiac Procedures

The high cost of AMI treatment and cardiac procedures presents a significant restraint in the global acute myocardial infarction (AMI) market. Treatment for AMI often involves a combination of pharmaceutical therapies, medical devices, and surgical interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). This high cost can limit patient access to optimal care, particularly in low-income populations or in developing regions, where healthcare resources are more constrained. Furthermore, the long-term care and rehabilitation required after an AMI event can add to the financial burden on patients and healthcare systems.

According to the American Heart Association, Inc., research data in February 2024 stated that the economic burden of treatment varies significantly based on the intervention required. The cost of managing an AMI event without percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is the lowest, averaging $21,898.

However, the financial impact increases substantially with more advanced procedures, with AMI cases requiring PCI costing approximately $31,522, while those necessitating CABG rise to $71,788 more than three times the cost of AMI management without these interventions. These high treatment expenses present a significant restraint in the global AMI market, influencing healthcare accessibility, reimbursement policies, and overall cost-effectiveness considerations for cardiovascular care. Thus, the above factors could be limiting the global acute myocardial infarction market's potential growth.

Segment Analysis

The global acute myocardial infarction market is segmented based on treatment type, route of administration and region.

Treatment Type:

The antiplatelet agents segment in treatment type is expected to dominate the global acute myocardial infarction market with the highest market share

Acute myocardial infarction (AMI) is a critical cardiovascular condition that significantly contributes to global morbidity and mortality. In the global AMI market, antiplatelet therapies play a vital role in managing the condition by reducing the risk of major adverse cardiovascular events and recurrent myocardial infarction (MI). These treatments are essential for improving patient outcomes and are a key focus of ongoing advancements in cardiovascular care.

According to the Cureus research publication in March 2023, antiplatelet therapies such as abciximab, tirofiban, and eptifibatide are widely utilized in the treatment of ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

These agents are commonly administered alongside standard therapies, including aspirin, clopidogrel, prasugrel, and anticoagulants like heparin or bivalirudin. Typically, abciximab and tirofiban are given as an IV bolus 10 to 60 minutes before PCI, followed by continuous infusion. Additionally, research has indicated that tirofiban and abciximab demonstrate comparable effectiveness in AMI treatment. These findings continue to shape the evolving landscape of antiplatelet therapies in the global AMI market. These factors have solidified the segment's position in the global acute myocardial infarction market.

Geographical Analysis

North America is expected to hold a significant position in the global acute myocardial infarction market with the highest market share

North America has a high incidence of cardiovascular diseases, including AMI, due to factors such as unhealthy diets, sedentary lifestyles, smoking, and high rates of obesity and diabetes. These risk factors significantly increase the prevalence of AMI, which drives demand for treatment options, including pharmaceuticals, medical devices, and surgical interventions.

According to the Centers for Disease Control and Prevention (CDC) stats in October 2024, in North America, particularly in the United States, a heart attack occurs every 40 seconds, with approximately 805,000 people experiencing a heart attack annually. This high incidence significantly drives the demand for acute myocardial infarction (AMI) treatments and related healthcare services, making the region a key market for cardiovascular care and innovative solutions aimed at reducing heart attack-related morbidity and mortality.

For instance, in March 2025, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved TNKase (tenecteplase), a thrombolytic agent, for the treatment of acute myocardial infarction (AMI) in adults. This approval strengthens Genentech's presence in the global AMI market, highlighting its commitment to advancing cardiovascular care. With TNKase and Activase (alteplase), Genentech remains a key player in developing FDA-approved therapies for AMI, reinforcing its leadership in innovative treatments for thrombotic conditions. Thus, the above factors are consolidating the region's position as a dominant force in the global acute myocardial infarction market.

Competitive Landscape

The major global players in the acute myocardial infarction market include AGEPHA Pharma FZ-LLC, Genentech, Inc., Sanofi, Boehringer Ingelheim International GmbH. (Eli Lilly and Company), Bayer AG, Daiichi Sankyo Company, Limited, AstraZeneca, Pfizer Inc., Fresenius Kabi, Viatris Inc. (Idorsia) and among others.

Key Developments

  • In February 2024, Global biotechnology leader CSL announced top-line results from the Phase 3 AEGIS-II trial, which assessed the efficacy and safety of CSL112 (apolipoprotein A-I [human]) in reducing major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The trial did not achieve its primary efficacy endpoint of MACE reduction at 90 days. Consequently, CSL has no immediate plans for a regulatory filing. However, the study found no significant safety or tolerability concerns associated with CSL112.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global acute myocardial infarction market report delivers a detailed analysis with 54 key tables, more than 51 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Treatment Type
  • 2.4. Snippet by Route of Administration
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Aging Population and Increasing Prevalence of Cardiovascular Conditions
      • 3.1.1.2. Growing Demand for Minimally Invasive Procedures
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of AMI Treatment & Cardiac Procedures
      • 3.1.2.2. Stringent Regulatory Approvals for New AMI Drugs & Devices
    • 3.1.3. Opportunity
      • 3.1.3.1. Expanding Use of Drug Therapies
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Acute Myocardial Infarction Market, By Treatment Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 5.1.2. Market Attractiveness Index, By Treatment Type
  • 5.2. Colchicine*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Tenecteplase
  • 5.4. Empagliflozin
  • 5.5. Antiplatelet Agents
    • 5.5.1. Aspirin
    • 5.5.2. Clopidogrel
    • 5.5.3. Prasugrel
    • 5.5.4. Ticagrelor
  • 5.6. Anticoagulants
    • 5.6.1. Unfractionated Heparin (UFH)
    • 5.6.2. Enoxaparin
    • 5.6.3. Dalteparin
    • 5.6.4. Bivalirudin
    • 5.6.5. Tinzaparin
  • 5.7. Glycoprotein IIb/IIIa inhibitor
  • 5.8. Antianginal therapy
  • 5.9. Beta-blocker
  • 5.10. ACE inhibitor
  • 5.11. Statin
  • 5.12. Devices
  • 5.13. Others

6. Acute Myocardial Infarction Market, By Route of Administration

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 6.1.2. Market Attractiveness Index, By Route of Administration
  • 6.2. Oral*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Intravenous (IV)
  • 6.4. Others

7. Acute Myocardial Infarction Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. U.K.
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. Latin America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Mexico
      • 7.4.5.2. Brazil
      • 7.4.5.3. Argentina
      • 7.4.5.4. Rest of Latin America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. AGEPHA Pharma FZ-LLC. *
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Genentech, Inc.
  • 9.3. Sanofi
  • 9.4. Boehringer Ingelheim International GmbH. (Eli Lilly and Company)
  • 9.5. Bayer AG
  • 9.6. Daiichi Sankyo Company, Limited
  • 9.7. AstraZeneca.
  • 9.8. Pfizer Inc.
  • 9.9. Fresenius Kabi
  • 9.10. Viatris Inc. (Idorsia)

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us